Paper
8 January 2024 Targeting KRAS G12C: progress made and promise ahead
Author Affiliations +
Proceedings Volume 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023); 129243Z (2024) https://doi.org/10.1117/12.3013204
Event: 3rd International Conference on Biological Engineering and Medical Science (ICBioMed2023), 2023, ONLINE, United Kingdom
Abstract
KRAS oncogenic mutations are existent in 15% of human malignancies, resulting in constitutive activation of KRAS. Prior attempts failed to target this protein leading to the claim that KRAS was undruggable. However, the disclosure of a new allosteric pocket on KRASG12C substantially empowers anti-KRAS drug design and represents an amazing breakthrough made by structural biology and medicinal chemistry efforts. AMG510 and MRTX849 are remarkable in the design of G12C covalent inhibitors and have shown encouraging results clinically, with several more anti-cancer therapeutic drugs targeting KRASG12C on the horizon. Herein we provide a brief review of the structure of KRAS, its function and KRAS-related pathway, and its common mutations in human tumors, especially KRASG12C. Then, we discuss the most recent advancements in developing KRASG12C covalent inhibitors, as well as their chemical structures as well as the challenging but promising future of new development and translational applications of KRASG12C inhibitor to improve human health.
(2024) Published by SPIE. Downloading of the abstract is permitted for personal use only.
Huiqi Dai, Shuang Fang, and Jinjie Song "Targeting KRAS G12C: progress made and promise ahead", Proc. SPIE 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023), 129243Z (8 January 2024); https://doi.org/10.1117/12.3013204
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Tumors

Proteins

Switches

Molecules

Cancer

Chemistry

Design and modelling

Back to Top